Pharma Focus America

Techno Trends

Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).

FDA Approves CARVYKTI® Breakthrough Therapy for Second-Line Multiple Myeloma

Legend Biotech Corporation has developed CARVYKTI®, a breakthrough therapy approved by the U.S. Food and Drug Administration for treating relapsed or refractory multiple myeloma....

FDA Approves Breyanzi® as First-of-Its-Kind Cell Therapy for Relapsed/Refractory CLL/SLL

Bristol Myers Squibb has recently announced the U.S. Food and Drug Administration accelerated approval of Breyanzi®, a CD19-directed chimeric antigen receptor...

UChicago Medicine to Offer Groundbreaking Treatment for Rare Metabolic Liver Disease

The University of Chicago Medicine is set to prescribe Resmetirom, a groundbreaking drug marketed as Rezdiffra. For the treatment of advanced metabolic dysfunction-associated steatotic liver disease...

First-of-Its-Kind Antibiotic-Resistant Bacteria Drugs Developed Using Generative AI

Researchers at Stanford Medicine and McMaster University are addressing the global challenge of antibiotic resistance using generative artificial intelligence....

RYBREVANT® Combination Therapy Novel FDA Approval for First-Line Non-Small Cell Lung Cancer Treatment

Johnson & Johnson revealed that the U.S. Food and Drug Administration has granted approval for the use of RYBREVANT® in combination with chemotherapy as a first-line treatment for patients diagnosed...

Novel WINREVAIR™ Receives FDA Approval as First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

Merck, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for sotatercept-csrk under the brand name WINREVAIR™. ...

UCF Researchers Unveil Revolutionary Treatment for Untreatable Brain Cancer

Researchers at the College of Medicine are pioneering a new approach to combat glioblastoma, an aggressive and currently incurable form of brain cancer. Despite existing treatments such as surgery, radiation, and chemotherapy, patients typically face a grim...

Biogen's SKYCLARYS® Receives Groundbreaking European Commission Approval as the First Treatment for Friedreich’s Ataxia

Biogen recently announced a groundbreaking development: the European Commission has officially authorized SKYCLARYS® for treating Friedreich’s ataxia in adults and adolescents aged 16 years and older. This marks a significant step forward as...

FDA Greenlights Mabwell's Innovative B7-H3 ADC 7MW3711 for Clinical Trials

Mabwell, an innovative biopharmaceutical company boasting a comprehensive industry chain, has received approval from the U.S. Food and Drug Administration for its clinical trial application of a novel B7-H3 targeting ADC, known as 7MW3711. This ADC,...

Iovance's Groundbreaking AMTAGVI™ (Lifileucel) Secures Accelerated FDA Approval to Revolutionize Advanced Melanoma Therapy

Iovance Biotherapeutics has gained approval from the U.S. Food and Drug Administration for AMTAGVI™ suspension for intravenous infusion. This treatment is tailored for adults facing unresectable or metastatic melanoma...

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024